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ABSTRACT
Niacin activates HCA2 receptor coupled to distal enzymes that results in the 
release of PGD2. However, little is known on PGD2-producing cells and the role 
of dietary fatty acids in the regulation of PGD2 production. With the exception of 
neutrophils and monocytes, all cells but notably M-CSF macrophages exhibited 
a timely dependent PGD2 production upon niacin challenge. Short pre-treatment
of M-CSF macrophages with autologous postprandial TRLs induced the down-
regulation of HCA2 gene and up-regulation of genes encoding COX1 and COX2
enzymes in a fatty acid-dependent manner. These effects were paralleled by a 
higher PGD2 production with postprandial TRL-SFAs. The niacin-mediated 
transcriptional activity of all genes involved in PGD2 biosynthesis was 
desensitized in a time-dependent manner by postprandial TRLs, leading to a 
decreased PGD2 release. In vivo, the net excursions of PGD2 in plasma from 
volunteers in response to the different dietary fatty acids plus a single-dose of 
immediate-release niacin followed similar fatty acid-dependent patterns as 
those found for PGD2 release in vitro. M1 and niacin-activated naïve 
macrophages are major PGD2-producing cells in the human monocyte-
macrophage lineage. The predominant fatty acid class in the diet acutely 
modulates PGD2 biosynthetic pathway both in vitro and in vivo.
Keywords: Niacin; exogenous fatty acids; postprandial state; prostaglandin D2;
myeloid cells
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1. Introduction
Niacin (also commonly known as nicotinic acid or vitamin B3) is well 
established for the treatment of dyslipidemia [1] and reduction of cardiovascular 
risk [2]. However, its clinical use has been greatly limited due to an intense skin 
flush within a few minutes of niacin ingestion [3]. This side effect is mediated by 
the niacin-induced agonism of hydroxy-carboxylic acid receptor 2 (HCA2) to 
produce the vasodilator prostaglandin D2 (PGD2) in epidermal Langerhans cells
and keratinocytes [4]. PGD2 is also an early-phase mediator in several 
inflammatory conditions [5] and hypersensitivity reactions such as anaphylaxis 
[6], with the major contribution from resident mast cells in peripheral tissues  [7]. 
The stimulation of HCA2 by niacin triggers a cascade of distal but functionally 
linked enzymes that encompasses the cytosolic phospholipase A2 (PLA2) for 
the release of endogenous arachidonic acid from the cell membrane, the 
constitutive cyclooxygenase isoform 1 (COX1) and the inducible 
cyclooxygenase isoform 2 (COX2) as the rate-limiting steps for the conversion 
of arachidonic acid into the unstable cyclic endoperoxide PGH2, and the PGD 
synthase (PTGDS) for the isomerization of PGH2 to yield PGD2 [8]. PGD2 can be
non-enzymatically dehydrated to form 15-deoxy-12,14 prostaglandin J2 (15d-
PGJ2), the most potent endogenous ligand of peroxisome proliferator-activated 
receptor  (PPAR) that drives the feedback regulation of gene encoding HCA2 
[9]. The PPARs are promiscuous in terms of their interaction with ligands and 
they also exhibit distinctive affinity for selective fatty acids, including saturated 
fatty acids (SFAs), monounsaturated fatty acids (MUFAs), and long-chain 
polyunsaturated fatty acids (PUFAs) of the omega-3 family exogenously 
supplied by postprandial triglyceride-rich lipoproteins (TRLs) [10]. These 
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observations raise the issue of whether the acute metabolism of dietary fatty 
acids might be linked to signaling mechanism for niacin-induced PGD2 
production.
The full-length cDNA of HCA2 was first cloned from a cDNA library of 
human monocytes [11] but other cells of innate immune system (neutrophils and
antigen-presenting cells derived from CD34+ umbilical blood precursor cells) 
also expressed HCA2 [12,13]. The physiological role of HCA2 and its contribution
to niacin-induced PGD2 production in monocytes and neutrophils is unclear. 
However, primary peritoneal macrophages from patients subjected to 
paracentesis and macrophage-like THP-1 cells following treatment with phorbol-
12-myristate-13-acetate have been shown to produce PGD2 by a COX-
dependent mechanism in response to niacin [14]. These data suggest that the 
niacin-HCA2 axis is usable for PGD2 production in the myeloid-differentiated 
lineage. In different tissue environments, monocyte myeloid cells can mature 
and differentiate into macrophages and dendritic cells (DCs) [15]; macrophages 
can further undergo polarization into M1 classical macrophages by Th1 
mediators and into M2 alternative macrophages by Th2 mediators [15]. Little is 
known regarding the niacin-induced PGD2 production in these cells.
In the present study, we sought first to determine the competence of 
primary monocytes, neutrophils, and four monocyte/macrophage-derived 
subsets (M-CSF macrophages as referred to only differentiated in M-CSF but 
not polarized macrophages, M1, M2 macrophages, and DCs) to produce PGD2 
upon niacin challenge. In M-CSF macrophages, which were the major niacin-
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induced PGD2-producing myeloid subset, the influence of niacin and 
postprandial TRLs with different class of predominant fatty acids (SFAs, MUFAs 
or omega-3 long-chain PUFAs) on the gene expression level and function of 
HCA2 and downstream signaling enzymes for PGD2 synthesis was also 
investigated.
2. Materials and methods
This study was conducted according to Good Clinical Practice Guidelines
and in line with the principles outlined in the Helsinki Declaration of the World 
Medical Association. Informed consent for the study was obtained (University of 
Seville, AGL2011-29008).
2.1. Postprandial TRL isolation
Oral fat emulsions were prepared according to the method described by 
our Patent WO/2014/191597. They consist of water, sucrose, fat (50 g/ m2 body 
surface area), emulsifier, and flavoring. Six volunteers, aged 25 to 35 years, 
non-smokers, with no medical history of disease known, abnormality of 
hematological or biochemical parameters were recruited. After an overnight 
fasting period of 12 h, all of them were given, over three different occasions, 
oral fat emulsions containing cow’s milk cream (meal rich in SFAs), refined olive
oil (meal rich in MUFAs) or refined olive plus a dose of omega-3 long-chain 
PUFAs, which consisted of 920 mg of eicosapentaenoic acid (EPA) and 760 mg
of docosahexaenoic acid (DHA) (meal rich in MUFAs + omega-3 long-chain 
PUFAs). At the postprandial lipemic peak, i.e. 2-3 h following the ingestion of 
the oral fat emulsion, venous blood was collected into K3EDTA-containing 
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Vacutainer tubes (Becton Dickinson, NJ, USA). TRLs were isolated, pooled, and
dialyzed against cold PBS [16]. TRLs were then immediately stored at -80 ºC. 
Lipid oxidizability of postprandial TRL was checked (TBARS level) during 
isolation and storage, but oxidation of lipids was not detected. TRLs were tested
for LPS contamination using the Pierce LAL Chromogenic Endotoxin 
Quantification kit (Thermo Scientific, Madrid, Spain). LPS contamination was 
always <0.2 EU/mL. Triglyceride concentration in postprandial TRLs was 
determined by colorimetric assay kit TG GPO-POD (Bioscience Medical, 
Madrid, Spain).
2.2. Fat and TRL fatty acid composition
The fatty acid composition of cow's milk cream, refined olive oil, and 
refined olive oil plus omega-3 long-chain PUFAs was determined, in triplicate 
from the same lot, by the method described in EEC/796/2002 [17] using a gas 
chromatography system (HP-5890, Hewlett-Packard) equipped with flame 
ionization detector and a SP-2380 capillary column (Supelco, 30 m  0.32 mm) 
packed with cyanopropyl siloxane (0.25 μm) (Table 1). The initial column 
temperature was 165 ºC, which was held for 10 min, then programmed from 
165 ºC to 200 ºC at 1.5 ºC/min. Injector and detector temperature were 250 ºC, 
with the carrier gas H2. For fatty acid composition in postprandial TRLs (named 
TRL-SFAs from cow’s milk cream, TRL-MUFAs from refined olive oil, and TRL-
MUFAs+3 from refined olive oil plus omega-3 long-chain PUFAs), aliquots of 
100 μL were lyophilized. A solution composed of 2.64 mL of 
methanol:toluene:dimethoxypropane:sulphuric acid (16.5:5:1:1) and heptane 
was added on the lyophilized residue. After shaking, and incubating the mixture 
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at 80 °C for 1 h, the upper phase was transferred to another vial and dried with 
a stream of N2 gas. The resulting extract was dissolved in heptane and the fatty 
acid methyl esters were analyzed into a gas chromatography system as 
described above (Table 2).
2.3. Monocyte and neutrophil isolation
The same six volunteers who took part as donors of postprandial TRLs 
participated as donors of leukocytes. After an overnight fasting period of 12 h, 
peripheral blood samples were drawn from a large antecubital vein and 
collected into K3EDTA-containing tubes (BD). Peripheral blood mononuclear 
cells (MNCs) were isolated by centrifugation over a Ficoll-Histopaque (Sigma, 
Madrid, Spain) gradient. Monocytes were isolated from peripheral blood MNCs 
using CD14 microbeads and LS columns on a midiMACS system (Miltenyi 
Biotec, Madrid, Spain). Neutrophils were isolated by dextran sedimentation (2% 
dextran/0.9% NaCl) (Sigma) from the fraction of peripheral blood 
polymorphonuclear cells (PMNCs). Residual erythrocytes were removed using 
hypotonic lysis with 0.2% and 1.6% saline solutions. Monocyte (CD14+) and 
neutrophil (CD16+) purity was routinely >90% by flow cytometry analysis 
(FACScanto II flow cytometer and FACSDiva software, BD) and cell viability 
>95% by trypan blue exclusion (Sigma). The monocytes and neutrophils were 
seeded at a density of 5105 cells/mL and 3106 cells/mL, respectively, and 
cultured in ultra low attachment flasks in RPMI 1640 medium supplemented 
with L-glutamine, penicillin, streptomycin, and 10% heat-inactivated fetal bovine 
serum (complete culture medium). PGD2 was determined in the medium of 
monocytes and neutrophils after 30 min.
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2.4. Monocyte differentiation and polarization
Monocytes were induced to differentiate for 6 days in the presence of 
human recombinant M-CSF (50 ng/mL) to obtain naïve (M-CSF) macrophages. 
Complete culture medium was replaced every 2 days with fresh medium and 
the cytokine. Degree of differentiation of the resulting population was 
determined for CD68 antigen using anti-human CD68 monoclonal antibody 
(Miltenyi Biotec) by flow cytometry analysis (more than 95% of cells were 
positive for CD68). A similar procedure but using human recombinant GM-CSF 
(50 ng/mL) and IL-4 (20 ng/mL) was follows to obtain DC-like cells from 
monocytes. For M1 or M2 polarization, M-CSF macrophages were exposed to 
LPS (100 ng/mL) and IFN (20 ng/mL) or to IL-4 (20 ng/mL), respectively, for 
additional 24 h. Gene expression levels of markers for DC (CD209 and CD1a), 
M1 (CD80 and CD64), and M2 (MRC1 and CD200R) were determined by RT-
qPCR.
2.5. Exposure conditions
Niacin was prepared as an aqueous stock solution further diluted into 
media without serum. In 24 well plates, cells were exposed to niacin (100 nM) 
for different times (0–180 min) in complete culture medium (1 mL/well). This 
niacin concentration induced maximum PGD2 release after exposure of cells to 
varying doses of niacin (10 nM-100 M) (data not shown). In some experiments,
cells were pre-incubated with aspirin (ASA, 100 μM, 30 min) or postprandial 
TRLs (TRL-SFAs, TRL-MUFAs and TRL-MUFAs+3, 100 μg TG/mL, 30 min) 
prior to niacin exposure. Cells were treated with postprandial TRLs from the 
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same volunteer (autologous interaction) and each experiment was done in 
triplicate. The experiments were conducted with only once thawed postprandial 
TRL samples. PGD2 was measured in cell culture supernatants.
2.6. Media LPS and mycoplasma contamination
All media were tested for LPS contamination using the Pierce LAL 
Chromogenic Endotoxin Quantification kit. LPS contamination was always <0.2 
EU/mL. All cells were tested and free of mycoplasma contamination (Neuron 
Bio, Granada, Spain).
2.7. PGD2 assay
PGD2 was measured using a commercially available competitive enzyme
immunoassay kit (Cayman Chemical, MI, USA). Because PGD2 is relatively 
unstable, all samples underwent a chemical conversion to the stable PGD2 
methoxime (PGD2-MOX) prior to assay and according to manufacturer's 
instructions. Samples were then incubated overnight at 4 °C in 96 well plates 
pre-coated with mouse monoclonal anti-rabbit IgG, in the presence of rabbit 
PGD2-MOX antibody and a PGD2-MOX-linked acetylcholinesterase tracer. The 
complex of PGD2-MOX (either free or tracer linked) and rabbit antibody binds to 
the pre-coated plates. Following washing, a solution containing 
acetylcholinesterase reagent was added to wells and plates were read at 
412 nm.
2.8. RNA isolation and qRT-PCR analysis
9
Total RNA was extracted by using Trisure Reagent (Bioline). RNA quality 
was assessed by A260/A280 ratio in a NanoDrop ND-1000 Spectrophotometer 
(Thermo Scientific). Briefly, RNA (1 µg) was subjected to reverse transcription 
(iScript, Bio-Rad, Madrid, Spain). An amount of 20 ng of the resulting cDNA was
used as a template for real-time PCR amplifications. The mRNA levels for 
specific genes were determined in a CFX96 system (Bio-Rad). For each PCR 
reaction, cDNA template was added to Brilliant SYBR green QPCR Supermix 
(Bio-Rad) containing the primer pairs for either gene or for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and hypoxanthine 
phosphoribosyltransferase (HPRT) as housekeeping genes (Table 3). All 
amplification reactions were performed in triplicate and average threshold cycle 
(Ct) numbers of the triplicates were used to calculate the relative mRNA 
expression of candidate genes. The magnitude of change of mRNA expression 
for candidate genes was calculated by using the standard 2-(ΔΔCt) method. All 
data were normalized to endogenous reference (GAPDH and HPRT) gene 
content and expressed as percentage of controls.
2.9. Acute response to dietary fats and niacin
The same six volunteers who took part as donors of postprandial TRLs or
leukocytes participated in this part of the study. After an overnight fasting period 
of 12 h, all of them were given oral fat emulsions as indicated above and a 
single dose of 2 g immediate-release niacin (Twinlab, UT, USA). Venous blood 
was collected into K3EDTA-containing Vacutainer tubes (BD) at time 0, 30, and 
60 min. PGD2 was measured in plasma samples.
10
2.10. Data analysis
All values are expressed as means ± standard deviations (SD). Data 
were evaluated with Graph Pad Prism Version 5.01 software (San Diego, CA, 
USA). Area under the curve (AUC) and incremental AUC (iAUC) (area above 
baseline) were calculated using the trapezoidal rule. The statistical significance 
of any difference in each parameter among the groups was evaluated by 
repeated measure one-way analysis of variance (ANOVA), following Tukey’s or 
Dunnett’s test for multiple comparisons. P values less than 0.05 were 
considered statistically significant.
3. Results
3.1. Monocytes and monocyte-derived macrophages and dendritic cells but not 
neutrophils release prostaglandin D2
The analysis of PGD2 in the medium of monocytes and neutrophils 
obtained from fasting peripheral blood samples of healthy volunteers is shown 
in Fig. 1A. While monocytes exhibited the capacity for PGD2 release (138  29 
pg/mL), neutrophils did not liberate PGD2 into the medium. Monocytes have 
been shown to differentiate into macrophages or DC-like cells when exposed to 
M-CSF alone or GM-CSF plus IL-4. In addition, M-CSF macrophages can be 
polarized into M1 classically activated macrophages by a further treatment with 
IFN plus LPS or into M2 alternatively activated macrophages with IL-4. 
Therefore, we investigated PGD2 release in all of these monocyte-derived cells 
(Fig. 1B). Gene expression of phenotypic markers for M1 and M2 
macrophages, and DCs is shown in Fig. 1C. In comparison with M-CSF 
macrophages, M1 macrophages overexpressed CD80 and CD64 genes, M2 
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macrophages overexpressed MRC1 and CD200R genes, and DCs 
overexpressed CD209 and CD1a genes. The medium of M1 macrophages had 
the largest amount of PGD2 and media of M2 macrophages and DCs the 
lowest, while PGD2 measured in the medium of M-CSF macrophages was in 
between (Fig. 1D). These observations unveil human primary monocytes and 
monocyte-derived cells, notably M1 macrophages, as producers of PGD2.
3.2. M-CSF macrophages are major producers of prostaglandin D2 in response 
to niacin
To explore the potential of niacin to induce PGD2 release in these cells, 
monocytes, neutrophils, M-CSF, M1 and M2 macrophages, and DCs were 
treated with niacin for a period of 180 min. Monocytes (Fig. 2A) and neutrophils 
(Fig. 2B) were not responsive to niacin. However, M-CSF (Fig. 2C), M1 (Fig. 
2D) and M2 (Fig. 2E) macrophages, and to a lesser extent DCs (Fig. 2F) 
liberated PGD2 in a time-dependent manner with a peak at 30 min. The iAUC for
PGD2 was 365  13 pg/mL/min for M-CSF macrophages, 239  9 pg/mL/min for 
M1 macrophages, 224  6 pg/mL/min for M2 macrophages, and 82  8 
pg/mL/min for DCs. Furthermore, the cells with the highest peak response were 
M-CSF macrophages, followed by M1 and M2 macrophages, and then DCs 
(Fig. 2G). These findings unveil M-CSF macrophages from human primary 
monocytes as major PGD2-producing cells in response to niacin.
3.3. Postprandial triglyceride-rich lipoproteins modulate prostaglandin D2 
pathway genes and release in niacin-treated M-CSF macrophages
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To investigate the mechanisms by which niacin induced PGD2 release in 
M-CSF macrophages, we analyzed the expression levels of inducible genes 
involved in niacin signaling to PGD2 production and release. By this approach, 
the potential crosstalk between niacin and postprandial TRLs was also 
explored. These lipoproteins were obtained after the ingestion of standardized 
meals only differing in the fatty acid composition  mainly containing SFAs 
(TRL-SFAs), MUFAs (TRL-MUFAs) or MUFAs + omega-3 long-chain PUFAs 
(TRL-MUFAs+3)   from the same volunteers from which circulating 
monocytes, to further derive M-CSF macrophages, were obtained. As observed 
with the non-steroidal anti-inflammatory drug and COX inhibitor aspirin, the 
transcriptional activity of HCA2 gene was diminished by a pre-treatment for 30 
min with postprandial TRLs in M-CSF macrophages (Fig. 3A). This effect was 
similar between the different postprandial TRLs but it was more potent than that 
induced by aspirin. The pre-treatment of M-CSF macrophages with aspirin also 
diminished PLA2G4D (Fig. 3B), PTGS1 (Fig. 3C), and PTGS2 (Fig. 3D) gene 
expression, which was in part expected [18], while postprandial TRLs did not 
change mRNA levels of PLA2G4D gene but increased those of PTGS1 and 
PTGS2 genes (TRL-SFAs > TRL-MUFAs = TRL-MUFAs+3). The expression of
PTGDS gene was not affected by any pre-treatment (Fig. 3E). The addition of 
niacin to these pre-treated cells provoked time-dependent gene expression 
changes of HCA2 (Fig. 3F). The mRNA levels of HCA2 gene peaked at 30 min 
in the presence of aspirin or postprandial TRLs but were sharply decreased in 
non-pre-conditioned cells. Niacin-induced kinetics of mRNA expression for 
PLA2G4D gene in cells pre-treated with aspirin or postprandial TRLs resembled
those observed for HCA2 gene (Fig. 3G). However, mRNA levels of PLA2G4D 
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gene peaked at 60 min with a larger response in niacin-treated but non-pre-
conditioned cells. These transient mRNA profiles were similar for PTGS1 gene 
(Fig. 3H) but more pronounced for PTGS2 (Fig. 3I) and PTGDS (Fig. 3J) 
genes. In further experiments, the pre-treatment of M-CSF macrophages with 
postprandial TRL-SFAs did not change mRNA levels of PPARG (Fig. 4A) or its 
related genes NAMPT (Fig. 4B) and SIRT1 (Fig. 4C) [19,20], which were 
increased with TRL-MUFAs and notably TRL-MUFAs+3. After the addition of 
niacin, PPARG gene expression was increased over time with a peak at 30 min 
in non-pre-conditioned cells (Fig. 4D). This effect was particularly strong in cells
pre-treated with aspirin but less intense in cells pre-treated with postprandial 
TRL-MUFAs and TRL-MUFAs+3. The peak was even prevented in cells pre-
treated with postprandial TRL-SFAs. Niacin also induced a maximum in the 
kinetic of mRNA expression for NAMPT gene at 60 min in non-pre-conditioned 
cells and in pre-treated cells with aspirin, and at 30 min in pre-treated cells with 
TRL-SFAs or TRL-MUFAs (Fig. 4E). However, NAMPT gene expression was 
almost unaffected in pre-treated cells with TRL-MUFAs+3. The mRNA levels of
SIRT1 gene peaked at 60 min in non-pre-conditioned cells but at 30 min in all of
pre-treated cells (Fig. 4F). PGD2 release was further analyzed (Fig. 5A). The 
pre-treatment of M-CSF macrophages with postprandial TRLs increased the 
amount of PGD2 in the medium (TRL-SFAs > TRL-MUFAs = TRL-MUFAs+3). 
Niacin did not further increase over time PGD2 release in cells pre-treated with 
postprandial TRLs, while induced a rise with a peak at 30 min in non-pre-
conditioned cells (Fig. 5B). The administration of a meal with no fat and a 
single-dose of immediate-release niacin resulted in a time-dependent increase 
of PGD2 in plasma from the volunteers during the postprandial period (Fig. 5C). 
14
This effect was dramatically enhanced by the inclusion and modulated by the 
fatty acid composition of dietary fatty acids in the meals (meal rich in SFAs > 
meal rich in MUFAs = meal rich in MUFAs + omega-3 long-chain PUFAs). 
These data unveil postprandial TRLs as modulators in a fatty-acid-dependent 
manner of PGD2 pathway genes and release in niacin-treated M-CSF 
macrophages. They also underscore the physiological relevance of dietary fatty 
acids on post-meal circulating levels of PGD2.
4. Discussion
PGD2 is a lipid mediator that plays a pivotal role in the regulation of 
several biological processes such as vasodilatation and inflammation. At sites of
inflammation, PGD2 is taken up by surrounding cells through G protein-coupled 
receptors [21] that mediate opposing signals in the promotion and resolution of 
the inflammatory response [22]. Therefore, the mechanisms involved in PGD2 
production deserve particular attention. While PGD2 is predominantly produced 
de novo by mast cells and in lower amounts by basophils, recent studies have 
reported that macrophages from cryopreserved human monocytes following 
differentiation in M-CSF may also secrete PGD2 in response to TNF, remaining
a background level of PGD2 release in the absence of stimulus [23]. Here, we 
found that human primary monocytes and subsets thereof, such as M-CSF 
macrophages (naïve cells not yet exposed to signals that promote activation 
and functional polarization), M1 and M2 polarized macrophages, and DC-like 
cells also produce PGD2. This metabolic ability of monocyte-derived cells was 
enhanced as monocytes were induced to differentiate, suggesting that PGD2 
synthesis is a conserved metabolic pathway in the monocyte/macrophage 
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lineage and that PGD2 may play a role in the function of the innate immune 
system. The higher PGD2 release in M1 than in M2 macrophages further 
indicates the major involvement of PGD2 in M1-mediated processes. In the 
spectrum of macrophage phenotypes and functions [15], M1 macrophages are 
mainly associated with chronic inflammation and impaired wound healing in 
diseases such as atherosclerosis [24], obesity and diabetes [25], 
glomerulonephritis [26], and encephalitis [27]. In representing the other extreme 
in a universe of diversity, M2 macrophages are often described as having anti-
inflammatory or reparative functions but their persistence can also induce pro-
inflammatory disorders such as cystic fibrosis [28] and asthma [29]. PGD2 has 
been shown to mediate these macrophage plasticity-dependent pathologies 
[5,30]. As PGD2 release was not detected in neutrophils, it is probably that 
neutrophil-committed progenitors in the bone marrow lack the expression of any
critical element for PGD2 biosynthesis during maturation. The observation that 
DCs produced PGD2, as much as M2 and M-CSF macrophages, is in 
accordance with earlier identification of DCs as responsible for PGD2 detection 
in rat tissues [31] and argue for an effect of PGD2 in dictating the acquisition of 
immunostimulatory capacity by tissue-resident DCs [32].
Previous studies have shown the protective effect of HCA2 activation in 
raising PGD2 levels in animal tissues [33,34]. Niacin is a powerful stimulator of 
HCA2 [4]. We found that niacin treatment transiently increased PGD2 production 
in human monocyte-derived cells but not in monocytes or neutrophils. DCs were
the less and M-CSF macrophages were the most responsive cells to niacin. 
These observations suggest a new concept by which macrophage subsets and 
DCs are regulators of PGD2 levels through HCA2. We further investigated gene 
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expression levels of HCA2 and enzymes (PLA2, COX1, COX2, and PTGDS) 
involved in niacin-induced PGD2 production [8] in M-CSF macrophages. While 
HCA2 gene expression was rapidly suppressed, PLA2G4D, PTGS1, PTGS2, 
and PTGDS mRNA levels were transiently over-represented in response to 
niacin, supporting previous evidence of a negative feedback loop on HCA2 
following its activation [9,35]. This is also in line with the notion that niacin-
induced HCA2 receptor-dependent flushing may be desensitized within minutes 
[36]. In fasting conditions, the homeostatic function to restore the HCA2-PGD2 
axis is mediated by ketone bodies produced by the liver from circulating free 
fatty acids of adipose tissue origin [37]. This mechanism serves to prevent 
lipolysis, economizes triglyceride utilization, and maintains energy homeostasis 
during starvation [38]. It is a paradox that the suppression of lipolysis and free 
fatty acid influx into the bloodstream is also a characteristic feature of the non-
fasting state [39]. In response to the ingestion of a meal, exogenous fatty acids 
incorporated into postprandial TRLs take on the responsibility of meeting energy
needs for providing energy to cells for a positive balance [40]. However, the 
potential of fatty acids from postprandial TRLs to modulate HCA2, PLA2G4D, 
PTGS1, PTGS2 and PTGDS gene expression, and PGD2 production was 
unknown. We found that a short treatment (30 min) of M-CSF macrophages 
with postprandial TRLs decreased HCA2 mRNA levels as niacin similarly did, 
while cells lost their sensitivity to niacin in diminishing HCA2 mRNA levels over 
the time. This notion establishes a meaningful foundation for a possible 
regulatory crosstalk and interference between niacin and fatty acids from 
postprandial TRLs sensing the PGD2 biosynthetic pathway (Figure 6). 
Interestingly, PGD2-derived 15d-PGJ2 [9] and postprandial TRL-derived fatty 
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acids [10] are bona fide ligands for PPAR. In addition, due to its promiscuity for 
different fatty acids, the transcriptional activity of PPAR can be distinctively 
modulated by SFAs, MUFAs, and PUFAs [10]. We did not observe differences in
the expression of PLA2G4D and PTGDS genes in M-CSF macrophages upon 
challenge with postprandial TRLs rich in SFAs, MUFAs or MUFAs + omega-3 
long-chain PUFAs, but PTGS1 and PTGS2 genes were found to be up-
regulated by postprandial TRLs in a fatty acid-dependent manner (TRL-SFAs > 
TRL-MUFAs > TRL-MUFAs+3). Under these conditions, the smoothing of 
niacin-induced kinetics of mRNA for PGD2 biosynthetic genes and PGD2 release
suggests the occurrence of desensitization for PGD2 biosynthetic pathway, while
only PTGS1 and PTGS2 genes remaining transcriptionally modulated by the 
class of predominant fatty acids in postprandial TRLs. PPARG gene and its 
closely related NAMPT and SIRT1 genes [19,20] exhibited transcription patterns
similar to those seen for PTGS1 and PTGS2 genes. These transcriptomic 
changes and the lower PGD2 release with postprandial TRL-MUFAs or TLR-
MUFAs+3 than with postprandial TRL-SFAs, together with previous studies on 
PPAR stimulation by niacin-mediated 15d-PGJ2 in differentiated human 
monocytic cell lines [41], suggest that exogenous unsaturated fatty acids, 
probably via PPAR, are linked with COX enzymes to fine-tune the fuelling of 
PGD2 production in human macrophages. According to our findings on 
increased PGD2 production by postprandial TRL-SFAs and reports on short 
chain SFAs as powerful activators of human HCA2 [42], we cannot exclude the 
possible involvement of short-chain SFAs from TRL-SFAs in promoting PGD2 
production via this mechanism. Further investigations are needed to clarify 
these possibilities. Moreover, we observed that PGD2 was dramatically 
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increased in plasma from volunteers who ate a fatty meal rich in SFAs, MUFAs 
or MUFAs + omega-3 long-chain PUFAs and received a single dose of 
immediate-release niacin. Consistent with findings found in vitro, the magnitude 
of postprandial PGD2 responses was dependent on the type of dietary fatty 
acids ingested (meal rich in SFAs > meal rich in MUFAs > meal rich in MUFAs +
omega-3 long-chain PUFAs), but there was little if any desensitization effect. 
These observations may reflect the net impact of dietary fatty acids in the 
setting of niacin treatment on PGD2-producing cells and mechanisms other than
those we have explored in vitro.
Collectively, this study expands the knowledge on PGD2-producing cells 
and add novel insights into the mechanisms by which dietary fatty acids and 
niacin are involved in the control of metabolic pathways aimed at the production
and release of PGD2. In particular, we demonstrate that primary monocytes and 
monocyte-derived cells (M-CSF, M1 and M2 macrophages, and DCs) are well 
equipped with genes for PGD2 synthesis, although they secrete PGD2 
depending on the state of cellular differentiation. Those genes encoding COX1 
and COX2 may be modulated by postprandial TRLs depending on their 
predominant fatty acid class (SFAs, MUFAs or MUFAs + omega-3 long-chain 
PUFAs). M1 macrophages were the major producers and postprandial TRL-
SFAs were the major inducers of PGD2. Non-polarized macrophages gain 
advantage to secrete PGD2 in the presence of niacin, although this process is 
desensitized in a time-dependent manner by postprandial TRLs. Our 
observations led to new understanding into the dynamic role of dietary fatty 
acids for the control of niacin-induced PGD2 production and release by the 
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innate immune system, which could be of relevance in the management of 
PGD2-mediated disorders.
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Figure legends
Figure 1. Human primary monocytes and monocyte-derived cells, notably M1 
macrophages, secrete PGD2. Fasting healthy volunteers (n=6) were donors of 
peripheral blood mononuclear (MNCs) and polymorphonuclear (PMNCs) cells 
to isolate monocytes and neutrophils, respectively. Monocytes and neutrophils 
were incubated for 30 min in complete culture medium. Monocytes were 
differentiated in M-CSF (50 ng/mL) (naïve or M-CSF macrophages) or in GM-
CSF (50 ng/mL) plus IL-4 (20 ng/mL) (DC-like cells) for 6 days. M-CSF 
macrophages were further induced to polarize in LPS (100 ng/mL) plus IFN (20
ng/mL) (M1 macrophages) or in IL-4 (20 ng/mL) (M2 macrophages) for 
additional 24 h. A, PGD2 in monocyte and neutrophil supernatants. *P<0.01 vs 
neutrophils. B, Derivation and characteristics of monocyte-derived cells. C, 
Gene expression of some known markers of polarized macrophages (CD80 and
CD64 for M1, MRC1 and CD200R for M2) and DCs (CD209 and CD1a). 
*P<0.01 vs M-CSF macrophages. D, PGD2 in monocyte-derived cell 
supernatants. *P<0.01 vs other cell subset.
Figure 2. Human primary monocyte-derived cells, notably M-CSF 
macrophages, secrete PGD2 in response to niacin. A-F, PGD2 in monocyte (A), 
neutrophil (B), M-CSF macrophage (C), M1 macrophage (D), M2 macrophage 
(E), and DC-like cell (F) supernatants after niacin (100 nM) treatment for 180 
min. G, Percentages of PGD2 release vs non-treated cells. Each experiment 
was performed in triplicate. *P<0.01 vs t=0 min.
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Figure 3. Niacin and postprandial TRLs modulate the expression of HCA2 gene 
and genes involved in PGD2 biosynthesis in human M-CSF macrophages. 
Healthy volunteers (n=6) from which M-CSF macrophages were obtained, were 
also donors of postprandial TRLs after the ingestion of a standardized oral fat 
emulsion containing cow’s milk cream (TRL-SFAs), refined olive oil (TRL-
MUFAs) or refined olive plus a dose of omega-3 long-chain PUFAs (920 mg 
EPA and 760 mg DHA) (TRL-MUFAs+3). M-CSF macrophages and 
postprandial TRLs (100 μg TG/mL) from the same volunteer (autologous 
interaction) were incubated for 30 min. Cells were alternatively incubated with 
aspirin (100 μM). Thereafter, cells were treated with niacin (100 nM) for 180 
min. A-E, Gene expression of HCA2 (A), PLA2G4D (B), PTGS1 (C), PTGS2 
(D), and PTGDS (E) before niacin treatment. *P<0.01 vs control, **P<0.01 vs 
aspirin, ***P<0.01 vs other TRLs. F-J, Gene expression of HCA2 (F), PLA2G4D 
(G), PTGS1 (H), PTGS2 (I), and PTGDS (J) after niacin treatment. For the sake
of clarity, statistical differences are not shown. Each experiment was performed 
in triplicate.
Figure 4. Niacin and postprandial TRLs modulate the expression of PPARG 
gene and related genes NAMPT and SIRT1 in human M-CSF macrophages. 
Healthy volunteers (n=6) from which M-CSF macrophages were obtained, were 
also donors of postprandial TRLs after the ingestion of a standardized oral fat 
emulsion containing cow’s milk cream (TRL-SFAs), refined olive oil (TRL-
MUFAs) or refined olive plus a dose of omega-3 long-chain PUFAs (920 mg 
EPA and 760 mg DHA) (TRL-MUFAs+3). M-CSF macrophages and 
postprandial TRLs (100 μg TG/mL) from the same volunteer (autologous 
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interaction) were incubated for 30 min. Cells were alternatively incubated with 
aspirin (100 μM). Thereafter, cells were treated with niacin (100 nM) for 180 
min. A-C, Gene expression of PPARG (A), NAMPT (B), and SIRT1 (C) before 
niacin treatment. *P<0.01 vs control, **P<0.01 vs aspirin, ***P<0.01 vs other 
TRLs. D-F, Gene expression of PPARG (D), NAMPT (E), and SIRT1 (F) after 
niacin treatment. For the sake of clarity, statistical differences are not shown. 
Each experiment was performed in triplicate.
Figure 5. Postprandial TRLs induce PGD2 release in human M-CSF 
macrophages and dietary fats induce postprandial PGD2 excursions in a fatty 
acid-dependent manner. Healthy volunteers (n=6) from which M-CSF 
macrophages were obtained, were also donors of postprandial TRLs after the 
ingestion of an standardized oral fat emulsion containing cow’s milk cream 
(TRL-SFAs), refined olive oil (TRL-MUFAs) or refined olive plus a dose of 
omega-3 long-chain PUFAs (920 mg EPA and 760 mg DHA) (TRL-MUFAs+3). 
M-CSF macrophages and postprandial TRLs (100 μg TG/mL) from the same 
volunteer (autologous interaction) were incubated for 30 min. Cells were 
alternatively incubated with aspirin (100 μM). Thereafter, cells were treated with 
niacin (100 nM) for 180 min. Each experiment was performed in triplicate. In 
addition, the same volunteers were given a standardized oral fat emulsion 
containing the above dietary fats (meal rich in SFAs, MUFAs or MUFAs + 
omega-3 long-chain PUFAs) and a single dose of immediate-release niacin (2 
g). A, PGD2 in cell supernatants. *P<0.01 vs control, **P<0.01 vs aspirin, 
***P<0.01 vs other TRLs. B, Percentages of PGD2 release vs non-treated cells. 
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For the sake of clarity, statistical differences are not shown. C, PGD2 in post-
meal plasma. *P<0.01 vs control, **P<0.01 vs other TRLs.
Figure 6. Schematic representation of the different actions of niacin and fatty 
acids in postprandial TRLs in PGD2 production. The scheme summarizes the 
hypothesis by which niacin supplementation and fatty acids in dietary fats would
acutely modulate the biosynthesis of PGD2 in the human monocyte-
macrophage lineage. This model does not exclude the participation of additional
mechanisms of action for niacin and exogenous fatty acids to achieve their 
effects on the PGD2 biosynthetic pathway. Abbreviations can be found in the 
text.
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Table 1. Fatty acid composition of dietary fats.
Cow's milk
cream
Refined olive
oil
Refined olive
oil + omega-3
long-chain
PUFAs
Fatty acid g/100 g of fatty acid
4:0, butyric 0.83 ± 0.16 - -
6:0, caproic 0.25 ± 0.02 - -
8:0, caprylic 0.61 ± 0.07 - -
10:0, capric 2.47 ± 0.13 - -
12:0, lauric 3.09 ± 0.42 - -
14:0, myristic 10.9 ± 0.91 - -
16:0, palmitic 35.5 ± 0.82 20.4 ± 0.89 20.5 ± 0.64
16:1(-7), palmitoleic 3.60 ± 0.32 0.97 ± 0.17 0.82 ± 0.12
18:0, stearic 11.5 ± 0.75 5.70 ± 0.11 4.49 ± 0.36
18:1(-9), oleic 25.3 ± 0.71 61.9 ± 1.23 61.5 ± 0.97
18:2(-6), linoleic 4.27 ± 0.82 7.97 ± 0.65 8.04 ± 0.53
18:3(-3), α-linolenic 0.39 ± 0.05 1.04 ± 0.13 0.94 ± 0.03
20:5(-3), 
eicosapentaenoic
- - 0.92 ± 0.09
22:6(-3), 
docosahexaenoic
- - 0.72 ± 0.10
Others 0.96 ± 0.42 2.05 ± 1.08 2.01 ± 0.88
Data are means  SD (n=3).
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Table 2. Fatty acid composition of postprandial triglyceride-rich lipoproteins.
TRL-SFAs TRL-MUFAs TRL-MUFAs+3
Fatty acid g/100 g of fatty acid
4:0, butyric 0.22 ± 0.09 - -
6:0, caproic 0.13 ± 0.06 - -
8:0, caprylic 0.36 ± 0.12 - -
10:0, capric 1.42 ± 0.41 - -
12:0, lauric 3.77 ± 1.06 - -
14:0, myristic 9.04 ± 1.55 - -
16:0, palmitic 36.3 ± 2.31 11.8 ± 1.97 12.1 ± 1.34
16:1(-7), palmitoleic 1.59 ± 0.08 0.88 ± 0.32 1.46 ± 0.43
18:0, stearic 17.1 ± 1.54 5.98 ± 0.93 5.62 ± 0.83
18:1(-9), oleic 22.8 ± 2.03 66.4 ± 3.27 60.7 ± 2.18
18:2(-6), linoleic 4.24 ± 1.06 8.93 ± 1.27 10.1 ± 1.44
18:3(-3), -linolenic 2.00 ± 0.61 3.21 ± 1.12 3.17 ± 1.08
20:4(-4), arachidonic 0.53 ± 0.38 1.07 ± 0.21 1.82 ± 0.34
20:5(-3), 
eicosapentaenoic
- 0.82 ± 0.28 2.51 ± 0.38
22:6(-3), 
docosahexaenoic
- 0.74 ± 0.32 2.14 ± 0.03
Others 0.53 ± 0.26 0.23 ± 0.12 0.36 ± 0.24
Data are means  SD (n=18).
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Table 3. Sequences of RT-PCR primers for gene expression analysis.
Target GenBankaccession number Direction Sequence (5’→3’)
CD80 NM_005191.3
Forward
Reverse
GGGAAAGTGTACGCCCTGTA
GCTACTTCTGTGCCCACCAT
CD64 NM_000566.3
Forward
Reverse
GTCCAAATCTCCAAGTGCGG
CCCAAGTATGAGAGCAGCGT
MRC1 NM_138806
Forward
Reverse
GGCGGTGACCTCACAAGTAT
ACGAAGCCATTTGGTAAACG
CD200R NM_138940.2
Forward
Reverse
GTTGCCCTCCTATCGCATTA
TGGAAATTCCCATCAGGTGT
CD209 NM_021155.3
Forward
Reverse
CCAAAGGAGGAGACAAGCAG
GGACGACACGTTCAGTGTGA
CD1a NM_001763.2
Forward
Reverse
ATATGGCCAAGCATTTCTGC
ATCCTGAGACATGGCACACA
HCA2 NM_177551.3
Forward
Reverse
CACCGACAAGCAGAGAAACA
CACAGCAAAATGGAGCAGAA
PLA2G4D NM_178034.3
Forward
Reverse
TGGGAAGGAGGTGACTATGG
CTCATCCTCCTGCAGGTCTC
PTGS1 NM_000962.3
Forward
Reverse
GAGTACTGGAAGCCGAGCAC
GCACTCTGGAATGACAAGCA
PTGS2 NM_000963
Forward
Reverse
TTCAAATGAGATTGTGGAAAAAT
AGATCATCTCTGCCTGAGTATCTT
PTGDS NM_000954.5
Forward
Reverse
AACCAGTGTGAGACCCGAAC
AGGCGGTGAATTTCTCCTTT
PPARG NM_005037
Forward
Reverse
GCTGTGCAGGAGATCACAGA
GGGCTCCATAAAGTCACCAA
NAMPT NM_005746.2
Forward
Reverse
GCCAGCAGGGAATTTTGTTA
TGATGTGCTGCTTCCAGTTC
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SIRT1 NM_001142498.1
Forward
Reverse
GCAGATTAGTAGGCGGCTTG
TCTGGCATGTCCCACTATCA
GAPDH NM_001289746
Forward
Reverse
CACATGGCCTCCAAGGAGTAAG
CCAGCAGTGAGGGTCTCTCT
HPRT NM_000194
Forward
Reverse
ACCCCACGAAGTGTTGGATA
AAGCAGATGGCCACAGAACT
34






